Robust and durable prophylactic protection conferred by RNA interference in preclinical models of SARS-CoV-2
Anglero-Rodriguez, Y. I.; Lempp, F. A.; McIninch, J.; Schlegel, M. K.; Brown, C. R.; Foster, D. J.; Castoreno, A. B.; Nguyen, T.; Subramanian, M.; Montiel-Ruiz, M.; Kaiser, H.; Sahakyan, A.; Spreafico, R.; Morskaya, S. S.; Barry, J. D.; Berman, D.; Lefebvre, S.; Kasper, A.; Racie, T.; Weddle, D.; Mobley, M.; Rogers, A.; Dybowski, J.; Chong, S.; Nair, J.; Simon, A.; Sloan, K.; Hwang, S.; Virgin, H. W.; Fitzgerald, K.; Maier, M. A.; Hinkle, G.; Hebner, C.; Akinc, A.; Jadhav, V.
Show abstract
RNA interference is a natural antiviral mechanism that could be harnessed to combat SARS-CoV-2 infection by targeting and destroying the viral genome. We screened lipophilic small-interfering RNA (siRNA) conjugates targeting highly conserved regions of the SARS-CoV-2 genome and identified leads targeting outside of the spike-encoding region capable of achieving [≥]3-log viral reduction. Serial passaging studies demonstrated that a two-siRNA combination prevented development of resistance compared to a single-siRNA approach. A two-siRNA combination delivered intranasally protected Syrian hamsters from weight loss and lung pathology by viral infection upon prophylactic administration but not following onset of infection. Together, the data support potential utility of RNAi as a prophylactic approach to limit SARS-CoV-2 infection that may help combat emergent variants, complement existing interventions, or protect populations where vaccines are less effective. Most importantly, this strategy has implications for developing medicines that may be valuable in protecting against future coronavirus pandemics.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance 95%
- Identification of DAXX As A Restriction Factor Of SARS-CoV-2 Through A CRISPR/Cas9 Screen 95%
- A non-spike nucleocapsid R204P mutation in SARS-CoV-2 Omicron XEC enhances inflammation and pathogenicity 95%
Similar papers in this journal
Similar papers in this journal
- AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans 94%
- Rational design of a new class of protease inhibitors for the potential treatment of coronavirus diseases 93%
- Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers 93%
Similar papers in this journal
- A new level of RNA-based plant protection - dsRNAs designed from functionally characterized siRNAs highly effective against Cucumber Mosaic Virus 94%
- Cap-independent translation and a precisely localized RNA sequence enable SARS-CoV-2 to control host translation and escape anti-viral response 94%
- Mapping RNA-capsid interactions and RNA secondary structure within authentic virus particles using next-generation sequencing 94%
Similar papers in this journal
- Thiopurines inhibit coronavirus Spike protein processing and incorporation into progeny virions 95%
- Vaccinia virus D10 has broad decapping activity that is regulated by mRNA splicing 95%
- High-Throughput, Single-Copy Sequencing Reveals SARS-CoV-2 Spike Variants Coincident with Mounting Humoral Immunity during Acute COVID-19 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.